TPWM
DFTX

Twelve Points Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Twelve Points Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Buy
12,245
+1,600
+15% +$27.2K 0.05% 179
2025
Q4 		$147K Buy
+10,645
New +$132K 0.03% 192

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Twelve Points Wealth Management's DFTX Position: Q1 2026 in Review

Twelve Points Wealth Management increased its Definium Therapeutics (DFTX) stake by 15% in Q1 2026, buying an estimated $27.2K and bringing the position to 12,245 shares worth $231K. The position accounts for 0.05% of the portfolio, ranked #179.

Twelve Points Wealth Management first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Twelve Points Wealth Management held 12,245 shares of Definium Therapeutics worth $231K as of Q1 2026.
  • Twelve Points Wealth Management bought 1,600 Definium Therapeutics shares in Q1 2026, an estimated $27.2K.
  • Definium Therapeutics made up 0.05% of Twelve Points Wealth Management's portfolio in Q1 2026, its #179 holding.
  • Twelve Points Wealth Management first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Twelve Points Wealth Management's 13F filing for Q1 2026, filed 14 Apr 2026.